| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $154,628,092 ) (Continued on the next page) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA265928 | A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies | 000 | 5 | NIH | 3/3/2026 | $674,251 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Cancer - a Multi-Site Randomized Controlled Trial | 000 | 4 | NIH | 8/6/2026 | $669,032 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 001 | 15 | NIH | 4/16/2026 | $75,920 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 000 | 15 | NIH | 1/27/2026 | $683,283 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK082889 | Transcriptional control and enhancer recruitment in mouse and human intestinal secretory differentiation | 000 | 14 | NIH | 2/26/2026 | $372,621 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1HL069249 | BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium | 001 | 26 | NIH | 6/18/2026 | $252,257 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA281840 | Immunotherapeutic targeting of gangliosides in Ewing Sarcoma | 000 | 4 | NIH | 8/26/2026 | $795,150 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 001 | 2 | NIH | 4/3/2026 | $201,524 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 000 | 2 | NIH | 3/23/2026 | $406,450 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 000 | 3 | NIH | 3/27/2026 | $712,559 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA197588 | Role of Phosphoinositides and Protein Kinases in the control of Cancer Metabolism | 000 | 10 | NIH | 7/21/2026 | $1,064,242 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | 000 | 7 | NIH | 4/1/2026 | $997,843 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK078081 | Metabolic crosstalks in regulation of beta-cell stress response and adaptation | 000 | 14 | NIH | 3/2/2026 | $488,374 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 000 | 2 | NIH | 6/10/2026 | $37,114 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99GM157510 | Revealing Cellular Determinants of LINE-1 Retrotransposition Outcomes | 000 | 2 | NIH | 7/29/2026 | $125,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24CA294203 | Enhancement and further development of informatics methods for long-read cancer sequencing | 002 | 3 | NIH | 8/13/2026 | $858,022 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA279891 | Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia | 000 | 3 | NIH | 2/27/2026 | $215,179 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142783 | Niche regulation of gastric epithelial cell differentiation | 000 | 1 | NIH | 3/19/2026 | $740,581 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA304367 | Targeting KAT6A/B activity to induce responsiveness to anti-GD2 immunotherapy in neuroblastoma | 000 | 1 | NIH | 9/7/2026 | $219,852 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA299840 | Daily Step Count, Patient- Reported Outcomes, and Recurrence-Free Survival in Early Breast Cancer Survivors | 000 | 1 | NIH | 9/2/2026 | $168,960 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA307720 | Advanced Integration and Validation of Predictive Models for Germline Pathogenic Variant Identification | 000 | 1 | NIH | 9/10/2026 | $796,311 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA303323 | Investigating the function of aberrant RNA in cancer | 000 | 1 | NIH | 9/4/2026 | $569,552 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM154489 | Expanding the understanding of tRNA lifecycle under cellular stress | 000 | 2 | NIH | 9/4/2026 | $81,580 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 001 | 1 | NIH | 3/27/2026 | $5,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35HL183474 | Elucidating the Origins and Drivers of Clonal Dynamics in Hematopoiesis | 000 | 1 | NIH | 3/10/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 002 | 1 | NIH | 4/24/2026 | $5,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 000 | 1 | NIH | 3/9/2026 | $15,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | DP2GM170825 | De novo design of allosteric proteins that sense and respond to small molecules | 000 | 1 | NIH | 8/25/2026 | $845,500 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA304011 | Prospective Dynamic BH3 Profiling for Clinical Use in Relapsed or Refractory AML | 000 | 1 | NIH | 9/1/2026 | $388,616 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA300940 | The biology and phenotypic consequences of B-cell clonality driven by mosaic chromosomal alterations | 000 | 1 | NIH | 4/27/2026 | $235,491 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA315392 | Structural and mechanistic studies of the RAS/RAF MAPkinase pathway | 000 | 1 | NIH | 8/27/2026 | $657,443 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA307422 | Reprogramming tumor-associated macrophages with theranostic nanoparticles | 000 | 1 | NIH | 7/6/2026 | $454,109 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA307360 | Therapeutic vulnerabilities of ARID1A-mutant and -wildtype ovarian clear cell carcinoma | 000 | 1 | NIH | 8/20/2026 | $528,099 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA315599 | Dissecting Oxygen Sensing and PTEN Loss in FDG/Fluciclovine Uptake as Markers of PSMA Radioligand Therapy Resistance | 000 | 1 | NIH | 8/24/2026 | $170,639 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA302918 | From biology to therapy: mechanism-informed targeting in translocation renal cell carcinoma | 000 | 1 | NIH | 6/30/2026 | $737,086 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA312664 | Structure-function and mechanistic studies of a specific glycosyltransferase complex in fusion-driven pediatric gliomas | 000 | 1 | NIH | 6/12/2026 | $134,919 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303520 | Flipping the Switch in Cell Cycle Control: Dissecting the Molecular Mechanisms Governing Wee1 Kinase transition from Cdk Inhibitor to Substrate | 000 | 1 | NIH | 6/12/2026 | $645,102 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R33CA302616 | Gene delivery to antigen-specific T cells via targeted retroviral vectors to treat cancer | 000 | 1 | NIH | 8/17/2026 | $432,050 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13CA322631 | Bioconductor Conference: Expanding Training, Mentorship, and Collaboration in Genomic Data Science | 000 | 1 | NIH | 8/6/2026 | $75,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA298970 | SPORE in Leukemia | 000 | 1 | NIH | 8/12/2026 | $2,433,959 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32HL182347 | Examining the role of adenosine-sensing by macrophages in obesity-induced cardiac inflammation | 000 | 2 | NIH | 9/9/2026 | $76,780 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA311335 | USP1 inhibitor-mediated reversal of PARP inhibitor resistance in ovarian cancer. | 000 | 1 | NIH | 6/12/2026 | $463,279 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK146509 | A small-molecule methyltransferase as a direct target of metformin | 001 | 1 | NIH | 2/27/2026 | $0 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK146509 | A small-molecule methyltransferase as a direct target of metformin | 000 | 1 | NIH | 2/27/2026 | $78,040 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA312809 | Defining epigenetic underpinnings of neuroendocrine lineage carcinomas | 000 | 1 | NIH | 6/30/2026 | $170,394 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA316481 | TRIM28 Inhibition as a Synthetic Lethal Strategy for Small Cell Lung Cancers with NOTCH2-Inactivation | 000 | 1 | NIH | 8/24/2026 | $609,130 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA301574 | TIRR/53BP1 complex regulates mitotic fidelity and immune-mediated radiation response | 000 | 1 | NIH | 3/24/2026 | $683,075 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303628 | Novel functions of cell cycle proteins in G1/S phase progression and in cancer | 000 | 1 | NIH | 8/13/2026 | $606,749 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | OT2CA319961 | ILLUMINE - Exploiting the Dark Proteome to fight cancer | 000 | 1 | NIH | 8/5/2026 | $1,156,827 |
|
